Caribou Biosciences Sees Unusually High Options Volume (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) was the recipient of some unusual options trading on Monday. Stock traders purchased 2,025 call options on the company. This represents an increase of 535% compared to the average daily volume of 319 call options.

Analyst Ratings Changes

A number of analysts have weighed in on CRBU shares. Truist Financial set a $7.00 price target on Caribou Biosciences in a research note on Tuesday. Citigroup raised their price target on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded Caribou Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 24th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Caribou Biosciences Trading Down 10.7%

Shares of CRBU opened at $2.17 on Wednesday. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $3.54. The stock’s 50 day moving average is $2.20 and its two-hundred day moving average is $1.68. The firm has a market capitalization of $202.08 million, a PE ratio of -1.22 and a beta of 2.59.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. The company had revenue of $2.67 million during the quarter, compared to the consensus estimate of $1.64 million. On average, sell-side analysts predict that Caribou Biosciences will post -1.64 EPS for the current year.

Institutional Investors Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of CRBU. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Caribou Biosciences during the 1st quarter valued at approximately $559,000. Aberdeen Group plc lifted its position in shares of Caribou Biosciences by 118.3% during the 2nd quarter. Aberdeen Group plc now owns 897,579 shares of the company’s stock valued at $1,131,000 after acquiring an additional 486,435 shares during the period. AQR Capital Management LLC lifted its position in shares of Caribou Biosciences by 741.6% during the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock valued at $480,000 after acquiring an additional 463,391 shares during the period. Nuveen LLC acquired a new stake in shares of Caribou Biosciences during the 1st quarter valued at approximately $302,000. Finally, Envestnet Asset Management Inc. lifted its position in shares of Caribou Biosciences by 626.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 318,657 shares of the company’s stock valued at $402,000 after acquiring an additional 274,812 shares during the period. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.